Bio-Rad Laboratories Dividends and Buybacks
Dividend criteria checks 0/6
Bio-Rad Laboratories does not have a record of paying a dividend.
Key information
n/a
Dividend yield
3.8%
Buyback Yield
| Total Shareholder Yield | 3.8% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Bio-Rad: Uncertainties And Conservatism Continue To Hold Stock Back From Its Full Potential
Jan 29Getting In Cheap On Bio-Rad Laboratories, Inc. (NYSE:BIO) Is Unlikely
Jan 06
Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?
Dec 16Why Bio-Rad Laboratories Is Overvalued: A Fundamental And DCF Analysis
Nov 25Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Potentially Undervalued?
Nov 25A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Nov 04Bio-Rad Laboratories: Overvalued Given Current Growth Prospects
Sep 23We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Sep 08Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Shares May Have Run Too Fast Too Soon
Jul 18Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar
Jul 14Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet
Apr 18Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker
Apr 14At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?
Feb 07Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance
Oct 25Bio-Rad: A Cash Flow Returns On Investments Analysis
Aug 10Bio-Rad Labs reports Q4 2022 results
Feb 16Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals
Jan 04Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M
Oct 27Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal
Oct 12Bio-Rad Laboratories hits 52-week low; down 40% YTD
Sep 19Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M
Jul 28Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if BIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BIO's dividend payments have been increasing.
Dividend Yield vs Market
| Bio-Rad Laboratories Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (BIO) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Life Sciences) | 0.6% |
| Analyst forecast (BIO) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate BIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate BIO's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BIO has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/29 13:30 |
| End of Day Share Price | 2025/01/29 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bio-Rad Laboratories, Inc. is covered by 26 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Jon Wood | BofA Global Research |
| Sel Hardy | CFRA Equity Research |